FAILURE OF CORRELATION BETWEEN B7 EXPRESSION AND ACTIVATION OF INTERLEUKIN-2-SECRETING T-CELLS

被引:24
作者
LOMBARDI, G [1 ]
SIDHU, S [1 ]
DODI, T [1 ]
BATCHELOR, R [1 ]
LECHLER, R [1 ]
机构
[1] ROYAL POSTGRAD MED SCH,DEPT IMMUNOL,LONDON W12 0NN,ENGLAND
关键词
T CELL CLONES; TRANSFECTANTS; PRIMARY ALLORESPONSE; B7; CO-STIMULATION;
D O I
10.1002/eji.1830240305
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It is well established that triggering interleukin-2 (IL-2) secretion by helper T cells requires the T cell to receive at least two discrete signals. One signal is transduced by the CD3 complex, usually as the result of T cell receptor (TcR) occupancy, the second, or co-stimulatory, signal involves a non-cognate interaction between cell surface accessory molecules on the antigen-presenting cell (APC) and the T cell. A molecular interaction that has been implicated in the provision of costimulatory signals is that between B7/BB1 on the APC and its ligands, CD28 and CTL-A4 on the T cell. We have studied the ability of HLA-class II antigen-positive human T cells and a population of DR1-expressing transfected human fibroblasts to stimulate a proliferative response by human T cell clones, and by freshly isolated peripheral blood T cells. Despite their high levels of B7 expression, the T cell clones, were unable to induce proliferation or IL-2 secretion by DR-restricted, antigen-specific T cells. In contrast, the DR1-expressing transfectants, that were B7 negative, induced a strong proliferative response. When these two populations of DR-expressing cells were used to stimulate a primary alloresponse the results were reversed, in that the T cell clones induced a strong alloresponse but the transfected fibroblasts induced no proliferation. These results suggest that the expression of B7 may be necessary for costimulation of unprimed T cells, but not of established T cell clones. Furthermore the data show that the expression of B7 by an APC does not necessarily lead to IL-2 production or protection from the induction of tolerance. The mechanisms responsible for the inability of these T cells to provide full activation signals when used as APC is currently under investigation.
引用
收藏
页码:523 / 530
页数:8
相关论文
共 39 条
[1]   CD28 INTERACTION WITH B7-COSTIMULATES PRIMARY ALLOGENEIC PROLIFERATIVE RESPONSES AND CYTOTOXICITY MEDIATED BY SMALL, RESTING LYMPHOCYTES-T [J].
AZUMA, M ;
CAYABYAB, M ;
BUCK, D ;
PHILLIPS, JH ;
LANIER, LL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :353-360
[2]   B70 ANTIGEN IS A 2ND LIGAND FOR CTLA-4 AND CD28 [J].
AZUMA, M ;
ITO, D ;
YAGITA, H ;
OKUMURA, K ;
PHILLIPS, JH ;
LANIER, LL ;
SOMOZA, C .
NATURE, 1993, 366 (6450) :76-79
[3]   FUNCTIONAL EXPRESSION OF B7/BB1 ON ACTIVATED LYMPHOCYTES-T [J].
AZUMA, M ;
YSSEL, H ;
PHILLIPS, JH ;
SPITS, H ;
LANIER, LL .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (03) :845-850
[4]   ANALYSIS OF ACCESSORY SIGNALING IN HUMAN T-CELL CLONES [J].
BAL, V ;
LAMB, J ;
LECHLER, R .
HUMAN IMMUNOLOGY, 1993, 37 (02) :101-107
[5]  
BRODSKY FM, 1982, J IMMUNOL, V128, P129
[6]   BINDING OF T-CELL RECEPTOR TO MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-II-PEPTIDE COMPLEXES AT THE SINGLE-CELL LEVEL RESULTS IN THE INDUCTION OF ANTIGEN UNRESPONSIVENESS (ANERGY) [J].
CELIS, E ;
SAIBARA, T .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (12) :3127-3134
[7]   ANTIGEN ANALOG MAJOR HISTOCOMPATIBILITY COMPLEXES ACT AS ANTAGONISTS OF THE T-CELL RECEPTOR [J].
DEMAGISTRIS, MT ;
ALEXANDER, J ;
COGGESHALL, M ;
ALTMAN, A ;
GAETA, FCA ;
GREY, HM ;
SETTE, A .
CELL, 1992, 68 (04) :625-634
[8]   SELECTIVE INDUCTION OF B7/BB-1 ON INTERFERON-GAMMA STIMULATED MONOCYTES - A POTENTIAL MECHANISM FOR AMPLIFICATION OF T-CELL ACTIVATION THROUGH THE CD28 PATHWAY [J].
FREEDMAN, AS ;
FREEMAN, GJ ;
RHYNHART, K ;
NADLER, LM .
CELLULAR IMMUNOLOGY, 1991, 137 (02) :429-437
[9]   STRUCTURE, EXPRESSION, AND T-CELL COSTIMULATORY ACTIVITY OF THE MURINE HOMOLOG OF THE HUMAN LYMPHOCYTE-B ACTIVATION ANTIGEN-B7 [J].
FREEMAN, GJ ;
GRAY, GS ;
GIMMI, CD ;
LOMBARD, DB ;
ZHOU, LJ ;
WHITE, M ;
FINGEROTH, JD ;
GRIBBEN, JG ;
NADLER, LM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (03) :625-631
[10]  
GALVIN F, 1992, J IMMUNOL, V149, P3802